Wednesday, July 8, 2026

pharma · Ovarian Cancer · Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer · ANIX

Anixa Biosciences

Anixa Biosciences is a pharma organization headquartered in San Jose, USA. It trades on NYSE under ticker ANIX. Primary therapeutic focus areas include Ovarian Cancer, Pathologic Stage IIA-IIIC Triple-Negative Breast Can

San Jose, USA HQ
1982 Founded
12 Employees
Public company Type
ANIX · NYSE Ticker
Company details
Status
Public
HQ
San Jose, USA
Founded
1982
Employees
12
Programs
2
Drugs
4
Patents
1
Clinical program

Follicle Stimulating Hormone Receptor T Cells

Phase 1 · small molecule · Ovarian Cancer

Follicle Stimulating Hormone Receptor T Cells for Ovarian Cancer is a Phase 1 program (small_molecule) at Anixa Biosciences Inc with 1 ClinicalTrials.gov record(s).

← All Anixa Biosciences Inc projects Phase 1 small molecule active

Internal code MCC-21113

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Anixa Biosciences Inc
Phase
Phase 1
Modality
small_molecule
Indication
Ovarian Cancer
Status
active
Trials
1